In the present study, we found that five (45.5%) of 11 high-grade adenosarcomas (all had SOG) and 3 (33.3%) of 9 low-grade adenosarcomas exhibited cyclin D1 immunoreactivity; however, no significant association was found between cyclin D1 immunoreactivity and tumor grade, the presence of SOG, or other clinicopathological parameters. The gene discussed is CCND1; the disease is adenosarcoma.